|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
EP0584266B1
(en)
|
1991-05-06 |
2003-09-03 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
|
|
EP0590058B1
(en)
|
1991-06-14 |
2003-11-26 |
Genentech, Inc. |
HUMANIZED Heregulin ANTIBODy
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
ATE139900T1
(de)
|
1992-11-13 |
1996-07-15 |
Idec Pharma Corp |
Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
WO1996009380A1
(en)
|
1994-09-23 |
1996-03-28 |
The University Of British Columbia |
Method of enhancing expression of mhc class i molecules bearing endogenous peptides
|
|
ATE197765T1
(de)
|
1994-10-03 |
2000-12-15 |
Us Gov Health & Human Serv |
Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
JPH11514853A
(ja)
|
1995-09-08 |
1999-12-21 |
ジエンザイム コーポレイション |
遺伝子治療のための改良されたａａｖベクター
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
EP0979281B1
(en)
|
1997-05-02 |
2005-07-20 |
Genentech, Inc. |
A method for making multispecific antibodies having heteromultimeric and common components
|
|
CA2300957A1
(en)
|
1997-08-15 |
1999-02-25 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
JP2001517454A
(ja)
|
1997-09-19 |
2001-10-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組換えアデノ随伴ウイルスの産生に有用な方法および細胞株
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
CN1348463A
(zh)
|
1998-08-07 |
2002-05-08 |
华盛顿大学 |
免疫学单纯疱疹病毒抗原及其使用方法
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
US6596535B1
(en)
|
1999-08-09 |
2003-07-22 |
Targeted Genetics Corporation |
Metabolically activated recombinant viral vectors and methods for the preparation and use
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
WO2001045737A2
(en)
|
1999-12-22 |
2001-06-28 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
JP4810042B2
(ja)
|
2000-01-21 |
2011-11-09 |
バイオヴェックス リミテッド |
ヘルペスウイルス株
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
NZ527687A
(en)
|
2001-05-11 |
2005-10-28 |
Wellstat Biolog Corp Formerly |
Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
|
|
CA2452517A1
(en)
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
DE60235041D1
(de)
|
2001-11-30 |
2010-02-25 |
Us Gov Health & Human Serv |
Und ihre verwendung
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
WO2003082200A2
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
US20050220818A1
(en)
|
2002-06-21 |
2005-10-06 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
CA2498297A1
(en)
|
2002-09-09 |
2004-03-18 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
HUE035898T2
(en)
|
2002-12-16 |
2018-05-28 |
Genentech Inc |
Immunoglobulin variants and their applications
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
ATE539162T1
(de)
|
2003-03-27 |
2012-01-15 |
Ottawa Hospital Res Inst |
Mutierte viren der vesikulären stomatitis und deren verwendung
|
|
MXPA05013879A
(es)
|
2003-06-18 |
2006-06-27 |
Genelux Corp |
Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
|
|
EP1668143B1
(en)
|
2003-09-30 |
2013-03-20 |
The Trustees of The University of Pennsylvania |
Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
|
|
JP2007511216A
(ja)
|
2003-11-17 |
2007-05-10 |
クルセイド ラボラトリーズ リミテッド |
変異ウイルス
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
PT1718677E
(pt)
|
2003-12-19 |
2012-07-18 |
Genentech Inc |
Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
|
|
WO2005100402A1
(en)
|
2004-04-13 |
2005-10-27 |
F.Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP4958555B2
(ja)
|
2004-09-22 |
2012-06-20 |
協和発酵キリン株式会社 |
安定化されたヒトＩｇＧ４抗体
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
EP1819823A2
(en)
|
2004-12-01 |
2007-08-22 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
KR101374454B1
(ko)
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
|
EP2963118B1
(en)
|
2005-06-01 |
2017-08-09 |
California Institute of Technology |
Method of targeted gene delivery using viral vectors
|
|
US8986672B2
(en)
|
2005-06-23 |
2015-03-24 |
The University Of Houston |
Use of mutant Herpes Simplex Virus-2 for cancer therapy
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
WO2008011636A2
(en)
|
2006-07-21 |
2008-01-24 |
California Institute Of Technology |
Targeted gene delivery for dendritic cell vaccination
|
|
EP2415783B1
(en)
|
2006-10-16 |
2016-12-14 |
Genelux Corporation |
Modified vaccinia virus strains for use in a diagnostic and therapeutic method
|
|
WO2008140621A2
(en)
|
2006-12-21 |
2008-11-20 |
Mount Sinai School Of Medicine Of New York University |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
JP5442452B2
(ja)
|
2007-02-16 |
2014-03-12 |
ウイルツ・バイオロジクス・リミテッド |
単純ヘルペスウイルスおよびウイルス複製法
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
US8563521B2
(en)
|
2007-06-21 |
2013-10-22 |
Technische Universitat Munchen |
Biological active proteins having increased in vivo and/or in vitro stability
|
|
JP2010533718A
(ja)
|
2007-07-18 |
2010-10-28 |
ジェネラックス・コーポレイション |
腫瘍溶解性ウイルス治療に付随する副作用の処置もしくは改善用医薬の製造における化学治療剤の使用
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
AU2008329518A1
(en)
|
2007-11-27 |
2009-06-04 |
Viventia Biotechnologies Inc. |
Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof
|
|
LT2222861T
(lt)
|
2007-12-11 |
2018-03-26 |
The University Of North Carolina At Chapel Hill |
Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
WO2009139921A2
(en)
|
2008-05-16 |
2009-11-19 |
Genelux Corporation |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
WO2009148488A2
(en)
|
2008-05-29 |
2009-12-10 |
The General Hospital Corporation |
Use of oncolytic herpes viruses for killing cancer stem cells
|
|
WO2010059253A2
(en)
|
2008-11-24 |
2010-05-27 |
Massachusets Institute Of Technology |
Methods and compositions for localized agent delivery
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2456786B2
(en)
|
2009-07-24 |
2017-04-19 |
Immune Design Corp |
Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
|
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JP2014509841A
(ja)
|
2011-01-18 |
2014-04-24 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌を治療するための組成物および方法
|
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
BR112014012819B1
(pt)
*
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
AU2013237900B2
(en)
|
2012-03-30 |
2017-07-27 |
Immune Design Corp. |
Lentiviral vector particles having improved transduction efficiency for cells expressing DC- SIGN
|
|
US10117896B2
(en)
|
2012-10-05 |
2018-11-06 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
MX2017000630A
(es)
|
2014-07-15 |
2017-04-27 |
Immune Design Corp |
Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
SMT202100467T1
(it)
*
|
2015-04-17 |
2021-09-14 |
Alpine Immune Sciences Inc |
Proteine immunomodulatorie con affinità regolabili
|
|
JP6859320B2
(ja)
|
2015-08-20 |
2021-04-14 |
フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． |
臓器不全の治療および予防用のｂ７−ｈ１融合ポリペプチド
|
|
EP3491013A1
(en)
*
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
*
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
FI3596116T3
(fi)
|
2017-03-16 |
2023-11-09 |
Alpine Immune Sciences Inc |
Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
|